This observation was translated clinically with an anti-CD22 scFv-ETA recombinant immunotoxin, BL22, in chemotherapy-resistant hairy-cell leukemia, where 11 out of 16 treated patients had complete remission. Here, CD22 is linked to hairy cell leukemia.